Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Tapan M. Kadia, Patrick K. Reville, Xuemei Wang, Caitlin R. Rausch, Gautam Borthakur, Naveen Pemmaraju, Naval G. Daver, Courtney D. Dinardo, Koji Sasaki, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Alessandra Ferrajoli, Kapil N. Bhalla, Elias Jabbour, Koichi Takahashi, Rashmi Malla, Kelly QuagliatoRashmi Kanagal-Shamanna, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences